This week’s Other Barks & Bites discusses crucial developments in legislation and patent law with bipartisan support in the Senate aimed at generics and pharmaceutical research. Additionally, a ruling from the Federal Circuit reaffirmed that Mylan's proposed ANDA label for an antipsychotic drug will lead to induced patent infringement. In related news, several significant financial and legislative updates are also highlighted, including Tencent's significant investment in Ubisoft and the introduction of new management frameworks by the USPTO to streamline patent workflows.
The Federal Circuit confirmed that Mylan's generic label in its ANDA could lead to induced infringement of Janssen's antipsychotic patents, emphasizing label intent.
As the Federal Circuit ruled, Mylan's proposed ANDA label carries the specific intent to guide health care providers, potentially leading to patent infringement.
Collection
[
|
...
]